San Diego’s Epic Sciences said today it has signed an agreement with LabCorp (NYSE: LH) to help speed up European clinical trials that are using Epic’s technology to identify tumor cells in the blood.
LabCorp, the Burlington, NC, company officially known as Laboratory Corporation of America, operates one of the world’s largest networks of medical laboratories for testing clinical samples. Under their agreement, LabCorp’s central lab in Belgium will pre-process blood samples from clinical trials throughout Europe and send prepared slides to Epic’s certified lab in La Jolla.
Epic, founded in 2008 with technology developed in the lab of Peter Kuhn, a cell biologist at The Scripps Research Institute in San Diego, describes its test as a “blood fluid biopsy” to detect and analyze circulating tumor cells in blood samples.
According to Epic Sciences, a benign solid tissue tumor appears to begin shedding tumor cells into the blood stream at the first signs of malignancy. The tumor cells circulate through the system (many are destroyed) and eventually stick to the inside wall of a distant blood vessel, where they can form secondary tumors through a process known as metastasis. Conventional cancer diagnostics cannot detect these rare tumor cells—a blood sample with 30 million cells on a prepared slide typically has only about five of these circulating tumor cells.
Epic uses fluorescent antibodies that bind to cytokeratins, a key protein in circulating tumor cells that can be used to identify different types of carcinomas. Epic says preparation of the slides is crucial, and one reason why the deal with LabCorp is important. The company uses a digital microscope and an image-processing algorithm to scan each slide for clumps of aberrant fluorescence. The process requires high-performance computing to help analyze and manage the data, and high-definition imaging to help cellular pathologists identify and analyze fluorescing clumps of the rare tumor cells.
Murali Prahalad, who was hired as Epic’s CEO in August, says the company’s technology can be used as a “companion diagnostic” to categorize patients for particular cancer drugs, based on … Next Page »